Overview Laverdia™-CA1 is the first oral tablet FDA conditionally approved to treat lymphoma in dogs.

  • Verdinexor is a selective inhibitor of nuclear export CRM1/XPO1 protein
  • The active ingredient in Laverdia-CA1 is verdinexor, a substance that works by preventing tumor suppressing proteins from leaving the nucleus of cells, resulting in disruption of cancer cell survival and eventual cancer cell death